UN court denies Mladic request for release on health grounds
THE HAGUE (Reuters) -A U.N. war crimes court on Tuesday denied an application by Bosnian Serb general Ratko Mladic, who is serving a life sentence for his role in the 1992-95 war in Bosnia, to be urgently released to Serbia on health grounds.
In a decision published on the court's website, the court said that while Mladic's health condition is precarious, it is stable and well managed at the U.N. detention centre in The Hague.
The specific medical conditions of the 83-year-old former general, convicted of genocide and crimes against humanity, are redacted in court papers but he is known to suffer cognitive impairments and was hospitalised at least twice this year, according to earlier court hearings and documents.
"Uncontradicted medical opinions indicate that Mladic is nearing the end of his life, a fate that is human," the president of the court Graciela Gatti Santana, said in the ruling.
She added, however, that the former general does not have an acute terminal illness which could justify his release.
Mladic led Bosnian Serb forces during Bosnia's 1992-95 war, part of the bloody break up of Yugoslavia. He was convicted on charges of genocide, crimes against humanity and war crimes including terrorising the civilian population of the Bosnian capital Sarajevo during a 43-month siege, and the killing of more than 8,000 Muslim men and boys taken prisoner in the eastern town of Srebrenica in 1995.
Solve the daily Crossword
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
6 hours ago
- Hamilton Spectator
PHOTO ESSAY: Starvation attacks the bodies of these children in Gaza
GAZA CITY, Gaza Strip (AP) — In some tents and shelters in northern Gaza, emaciated children are held in their parents' arms. Their tiny arms and legs dangle limp. Their shoulder blades and ribs stick out from skeletal bodies slowly consuming themselves for lack of food. Starvation always stalks the most vulnerable first. Kids with preexisting conditions, like cerebral palsy, waste away quickly because the high-calorie foods they need have run out, along with nutritional supplements. But after months of Israeli blockade and turmoil in the distribution of supplies , children in Gaza with no previous conditions are also starting to die from malnutrition, aid workers and doctors say. Over the past month, 25 children have died of malnutrition-related causes, according to the Gaza Health Ministry, though it's not known how many had other conditions. The ministry, part of the Hamas-run government, is staffed by medical professionals and its figures on war deaths are seen by the U.N. and other experts as the most reliable estimate of casualties. Salem Awad was born in January with no medical problems, the youngest of six children, his mother Hiyam Awad said. But she was too weak from lack of food to breastfeed him. For the first two months of Salem's life, there was a ceasefire in Gaza, and more aid entered, but even then it was hard to find milk for him, his mother said. In March, Israel cut off all food from entering the territory for more than 2 1/2 months. Since then, Salem has been wasting away. Now he weighs 4 kilograms (9 pounds), his mother said. 'He just keeps losing weight. At the hospital, they say if he doesn't get milk, he could die,' she said, speaking in the family's tent in Gaza City. Israel has been allowing a trickle of aid into Gaza since late May. After an international outcry over increasing starvation, it introduced new measures last weekend it says are intended to increase the amount of food getting to the population, including airdrops and pauses in military operations in some areas. But so far, they have not had a significant effect, aid groups say. Food experts warned this week the 'worst-case scenario of famine is playing out in Gaza.' The U.N. says the impact of hunger building for months is quickly worsening, especially in Gaza City and other parts of northern Gaza, where it estimates nearly one in five children is now acutely malnourished. Across Gaza, more than 5,000 children were diagnosed with malnutrition this month, though that is likely an undercount, the U.N. says. Malnutrition was virtually nonexistent before the war. Doctors struggle to treat the children because many supplies have run out, the U.N. says. Israel denies a famine is taking place or that children are starving . It says it has supplied enough food throughout the war and accuses Hamas of causing shortages by stealing aid and trying to control food distribution. Humanitarian groups deny that significant diversion of food takes place. Throughout nearly 22 months of war, the number of aid trucks has been far short of the roughly 500 a day the U.N. says is needed. The impact is seen most strongly in children with special needs — and those who have been grievously wounded in Israeli bombardment. Mosab al-Dibs, 14, suffered a heavy head wound on May 7 when an airstrike hit next to his family's tent. For about two months, he has been at Shifa Hospital, largely paralyzed, only partly conscious and severely malnourished because the facility no longer has the supplies to feed him, said Dr. Jamal Salha. Mosab's mother, Shahinaz al-Dibs, said the boy was healthy before the war, but that since he was wounded, his weight has fallen from 40 kilograms to less than 10 (88 to 22 pounds) At his bedside, she moves his spindly arms to exercise them. The networks of tiny blue veins are visible through the nearly transparent skin over his protruding ribs. The boy's eyes dart around, but he doesn't respond. His mother puts some bread soaked in water — the only food she can afford — into a large syringe and squirts it into his mouth in a vain attempt to feed him. Most of it dribbles out from his lips. What he needs is a nutrient formula suitable for tube feeding that the hospital doesn't have, Salha said. At a school-turned-shelter for displaced people in Gaza City, Samah Matar cradles her son Yousef as his little brother Amir lies on a cushion beside her — both of them emaciated. The two boys have cerebral palsy and also need a special diet. 'Before the war, their health situation was good,' said Matar. They could get the foods they needed, but now 'all those things have disappeared, and their health has declined continually.' Yousef, 6 years old, has dropped from 14 kilograms (30 pounds) before the war to 9 kilograms (19 pounds) now. His 4-year-old brother, Amir, has shrunk from 9 kilograms to under 6 (19 to 13 pounds), she said. ___ This is a documentary photo story curated by AP photo editors. Error! Sorry, there was an error processing your request. There was a problem with the recaptcha. Please try again. You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy . This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply. Want more of the latest from us? Sign up for more at our newsletter page .
Yahoo
7 hours ago
- Yahoo
Novo Nordisk shares dip further as Wegovy gains nearly erased
By Jacob Gronholt-Pedersen (Reuters) -Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later in the session, extending recent losses that threaten to wipe out all the gains since the drugmaker launched its blockbuster weight-loss treatment Wegovy four years ago. The fall on Friday means the Danish firm has dropped out of the top 10 constituents of the Europe-wide STOXX 600 index. Share price declines across the sector were prompted by U.S. President Donald Trump, who sent letters on Thursday to 17 major pharmaceutical firms, including Novo Nordisk, telling them to cut drug prices in the United States. Novo Nordisk on Tuesday slashed its forecast for 2025 sales growth due to competition from compounded, or copycat, versions of Wegovy and appointed veteran insider Maziar Mike Doustdar as its new CEO, prompting its shares to fall 23% on the day. Novo became Europe's most valuable listed firm after launching Wegovy in June 2021, worth some $650 billion in the middle of last year. But its shares have lost more than two-thirds since on concerns the drugmaker is losing ground in the obesity drug race. Its market cap is now $214.5 billion. "The U.S. healthcare system is complex, but Novo Nordisk will continue to work to find solutions that help people access the medicines they need at affordable prices," Novo said in an emailed statement. Novo's shares were around 2% lower at 1453 GMT, bringing this week's losses to around 30% - the stock's worst week ever. The European healthcare index was down around 1% to its lowest since April. "Trump doesn't have the mandate to tell Novo Nordisk how to price their products in the U.S., but investors are just panicking about the risk of another downgrade," said Nordnet analyst Per Hansen. The pressure to lower prices adds to Novo's problems in the United States, its biggest market. It faces competition from Eli Lilly and from compounders - custom-made medicines that are based on the same ingredients as branded drugs. "This is a repricing of the obesity market, it's a repricing of the United States as the world's most attractive drug market, and it's a repricing of the risk from Donald Trump," Hansen said. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
CVS second-quarter profit beats estimates, helped by medical cost oversight
By Amina Niasse NEW YORK (Reuters) -CVS Health beat Wall Street estimates for second-quarter profit on Thursday, as tight oversight of higher medical costs led to improved performance for its Aetna health insurance business. The company also flagged improved performance in its national pharmacy chain and pharmacy benefit management businesses. CVS reported an adjusted quarterly profit of $1.81 per share, above the average analyst estimate of $1.46 per share, according to LSEG data. For full-year 2025, the insurer raised its profit outlook to $6.30 to $6.40 per share, compared with an average analyst estimate of $6.12 as compiled by LSEG. It attributed the raised forecast to its second-quarter performance. CVS previously had expected full-year earnings per share of $6.00 to $6.20. CVS Health's Aetna insurance business reported a medical loss ratio, or the percentage of premiums spent on medical services, of about 89.9% in the second quarter. Analysts expected a ratio of 91.16%, according to LSEG estimates. It was the third quarter in a row that CVS beat earnings targets as the company works on a turnaround after having missed financial targets repeatedly last year. Those problems had stemmed from an unexpected sharp rise in medical costs in its Medicare Advantage plans for people aged 65 and older or with disabilities, and struggles with its pharmacies. "Nothing is a surprise to us this quarter," said CEO David Joyner in an interview with Reuters. Joyner, who joined the company last October, said the Aetna business experienced higher costs in its Medicare Advantage plans sold through groups such as employers or retiree organizations, but those costs were accurately anticipated. Aetna aims to reprice half of those plans for 2026, he added. CVS plans to close 250 brick-and-mortar pharmacies this year in an effort to cut costs, and the company is reducing its government-sponsored health insurance plans. Rivals including UnitedHealth, Elevance and Centene have detailed higher-than-expected medical costs for the second quarter due to a sicker patient profile and mismatched government payment rates, primarily in Medicaid plans for low-income people. Government payment pressure in Medicare Advantage plans has also squeezed insurer margins this year, with the Centers for Medicare and Medicaid Services changing its calculations of how to reimburse plans for their sickest members. Joyner said CVS's primary care unit for seniors, Oak Street Health, is impacted by these regulatory changes, but the changes are manageable. Revenue for CVS's health services segment, which houses its Caremark pharmacy benefit manager, rose 10.2%, due to a more favorable drug mix and plan renewals from existing clients, the company said. Revenue for the retail-pharmacy and drug-infusion business increased by 12.5% during the second quarter, which Joyner said was aided by increases in prescription volumes filled. Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
